TB-500 (Thymosin Beta-4 / active fragment)

Quick summary

TB-500 is a term used in research and online peptide communities to describe either synthetic Thymosin Beta-4 (Tβ4), a 43 amino-acid peptide naturally present in many tissues, or a biologically active 17 amino-acid fragment sometimes called the "actin-binding fragment." The naming is inconsistent across vendors and the scientific literature, which creates ambiguity about what a given product contains.

TB-500 is not approved as a medicine in any jurisdiction. The FDA, EMA, MHRA, TGA, and Health Canada have not authorised any Thymosin β4 product or TB-500 product for clinical use. Early-phase clinical studies of native Thymosin β4 have been conducted (notably in chronic wound healing and dry eye), but none has reached regulatory registration.

The claims circulating online about athletic recovery and injury repair are not backed by registered randomised controlled trials. The content below summarises what the published scientific literature on native Tβ4 does and does not show.

Discovery and development of Thymosin Beta-4

The thymosin family of peptides was first isolated from thymic tissue in the 1960s by Allan Goldstein and colleagues, who were searching for factors responsible for T-cell maturation.^[1] Early work focused on Thymosin Alpha-1 (which reached clinical investigation for immune modulation), and the beta-thymosins were characterised as a separate class.

Thymosin Beta-4 itself is encoded by the TMSB4X gene and is among the most abundant intracellular peptides in mammalian cells. Its biological role as an actin-sequestering protein was established in 1991 by Safer and colleagues, who showed that Tβ4 binds monomeric G-actin and thereby regulates the pool of actin available for polymerisation.^[2] This finding placed Tβ4 at the centre of cytoskeletal dynamics and prompted interest in its potential roles in wound healing, inflammation, and tissue repair.

RegeneRx Biopharmaceuticals conducted Phase 1 and Phase 2 trials of recombinant Thymosin β4 (RGN-137 for wounds, RGN-259 for dry eye) through the 2000s and 2010s. None of these programmes completed Phase 3 development with a successful registration package as of the last review date.^[4]

Structure

Native Thymosin Beta-4 (Tβ4) is a 43 amino-acid peptide with a molecular weight of approximately 4,964 daltons. It is predominantly unstructured in solution (intrinsically disordered) but adopts a partially helical conformation when binding actin.

The actin-binding activity of Tβ4 resides in a conserved motif, LKKTET (or closely related sequences), located in the central portion of the peptide. The 17 amino-acid fragment marketed as "TB-500" in research contexts is often described as Tβ4(17-23) extended to include this motif, though the exact sequence supplied commercially varies between manufacturers.

Because commercial products labelled "TB-500" are not subject to pharmaceutical manufacturing oversight, sequence identity and purity cannot be assumed from the label alone.

Proposed mechanisms of action

The following mechanisms have been proposed based on in-vitro and animal studies. Their relevance to human tissue repair after subcutaneous administration of commercial TB-500 products has not been established in controlled trials.

• G-actin sequestration: Tβ4 binds monomeric actin (G-actin) in a 1:1 complex, preventing its incorporation into actin filaments. By modulating the ratio of monomeric to filamentous actin, Tβ4 influences cell migration, morphology, and signalling.^[2]
• Promotion of cell migration: in fibroblast and endothelial cell culture models, exogenous Tβ4 has been shown to increase directional migration, which may be relevant to wound closure.^[3]
• Angiogenesis: Tβ4 has been reported to promote the formation of new blood vessels in corneal assays and in ischaemic heart models in rodents, possibly through upregulation of matrix metalloproteinases and growth factor signalling.^[4]
• Anti-inflammatory effects: some studies report that Tβ4 downregulates NF-κB signalling and reduces pro-inflammatory cytokine production in cell models, though these findings have not been consistently replicated.

Pharmacokinetics in summary

Published human pharmacokinetic data for subcutaneously administered Tβ4 or the TB-500 fragment are not available in the peer-reviewed literature as of the last review date. The following points reflect what is known or can be reasoned from first principles:

• Native plasma concentration: Tβ4 is present endogenously in human plasma at low nanomolar concentrations and is exported by activated platelets at wound sites.
• Peptide stability: as a small unmodified peptide, Tβ4 would be expected to be susceptible to proteolytic degradation in plasma; no specific half-life data from subcutaneous dosing in humans has been published.
• Absence of registered PK data: the early-phase clinical programmes (RegeneRx) studied topical and intravenous routes in specific wound settings; no published study characterises subcutaneous bioavailability in healthy volunteers.

Research overview

Clinical research on native Thymosin β4 has proceeded through early-phase studies in two main areas:

• Chronic wound healing: RegeneRx conducted Phase 2 trials of topical RGN-137 (Tβ4 gel) in venous stasis ulcers and epidermolysis bullosa. Results showed some improvement in wound area reduction but Phase 3 was not initiated. These trials evaluated topical application, not subcutaneous injection.
• Dry eye disease: RGN-259 (Tβ4 eye drops) was assessed in Phase 2/3 trials for dry eye; results were mixed and no product has been registered.

Animal studies in cardiac ischaemia, peripheral nerve injury, and musculoskeletal models have shown regenerative effects in rodents, but species differences in peptide biology and the absence of adequate human trials mean these findings cannot be directly translated to expected clinical outcomes in humans.

No registered randomised controlled trial data exist for subcutaneous TB-500 in any human therapeutic context.

Safety overview

Because TB-500 as a subcutaneous product has not been studied in formally regulated human trials, there is no controlled adverse event dataset from which to draw conclusions. The following points represent the best available assessment:

• Early-phase trial safety: in the RegeneRx topical studies, Tβ4 appeared generally well tolerated locally, with injection-site reactions reported in intravenous studies. No serious drug-related adverse events were attributed to Tβ4 in published Phase 1/2 reports.
• Unknown subcutaneous profile: injection-site reactions, systemic distribution, and off-target effects of subcutaneous commercial TB-500 are not characterised in peer-reviewed safety studies.
• Product quality uncertainty: commercial peptides sold outside pharmaceutical regulation can contain incorrect sequences, impurities, or endotoxins. These are safety risks independent of the peptide's intrinsic biology.

Regulatory status

TB-500 and Thymosin Beta-4 are not approved as medicines in any of the five jurisdictions covered by this hub (US, EU, UK, AU, CA). The relevant regulatory positions are:

• United States: the FDA has not approved any Thymosin β4 product. TB-500 is not listed in FDA-approved drug databases. Importation and use in clinical contexts without IND coverage would not comply with US drug law.
• European Union / UK: no EMA or MHRA marketing authorisation exists for any Tβ4 product.
• Australia / Canada: not registered by TGA or Health Canada.

Possession and purchase laws for unscheduled research peptides vary by jurisdiction and are separate from approval status. Readers should consult local regulatory guidance.